Creating targeted immunotherapies for treatment-resistant cancers.
Creating targeted immunotherapies for treatment-resistant cancers.
About Duet
Duet Therapeutics is a clinical-stage immuno-oncology company creating a new category of bifunctional and cell-selective oligonucleotide treatments designed to target dormant immune cells within the tumor microenvironment. Targeted activation of these antigen-presenting cells removes the immunosuppressive shield around the tumor and jump-starts T cell-mediated immune responses to kill cancer cells.
The unique mechanism-of-action of these synthetic oligos comes from simultaneously targeting two intracellular immune pathways, signal transducer and activator of transcription 3 (STAT3) and toll-like receptor 9 (TLR9). The targeted inhibition of STAT3, a master immune checkpoint inhibitor, reawakens immune cells and allows for the full potential of TLR9-driven immune responses.
The broad, anticancer efficacy of these bifunctional and cell-selective oligos has been verified in numerous animal studies, using both human and mouse tumor models. These preclinical results underscore the therapeutic potential not only for blood cancers but also for the most aggressive solid tumors, such as metastatic prostate cancers.
